Sifuvirtide, a potent HIV fusion inhibitor peptide
- 8 May 2009
- journal article
- research article
- Published by Elsevier BV in Biochemical and Biophysical Research Communications
- Vol. 382 (3), 540-544
- https://doi.org/10.1016/j.bbrc.2009.03.057
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Anti-HIV-1 activities of compounds isolated from the medicinal plant Rhus chinensisJournal of Ethnopharmacology, 2008
- Design and Evaluation of Sifuvirtide, a Novel HIV-1 Fusion InhibitorOnline Journal of Public Health Informatics, 2008
- Pharmacokinetics of sifuvirtide, a novel anti-HIV-1 peptide, in monkeys and its inhibitory concentration in vitro1Acta Pharmacologica Sinica, 2005
- The anti-HIV-1 effect of scutellarinBiochemical and Biophysical Research Communications, 2005
- Rational design of highly potent HIV-1 fusion inhibitory proteins: Implication for developing antiviral therapeuticsBiochemical and Biophysical Research Communications, 2005
- Different from the HIV Fusion Inhibitor C34, the Anti-HIV Drug Fuzeon (T-20) Inhibits HIV-1 Entry by Targeting Multiple Sites in gp41 and gp120Online Journal of Public Health Informatics, 2005
- Enfuvirtide, a new drug for HIV infectionThe Lancet, 2003
- The Safety, Plasma Pharmacokinetics, and Antiviral Activity of Subcutaneous Enfuvirtide (T-20), a Peptide Inhibitor of gp41-Mediated Virus Fusion, in HIV-Infected AdultsAIDS Research and Human Retroviruses, 2002
- Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entryNature Medicine, 1998
- Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection.Proceedings of the National Academy of Sciences of the United States of America, 1994